Detailed Information on Publication Record
2024
An extensive immunohistochemical analysis of 290 ovarian adult granulosa cell tumors with 29 markers
NEMEJCOVA, Kristyna, Adam SAFANDA, Michaela KENDALL BARTU, Romana MICHALKOVA, Marian SVAJDLER et. al.Basic information
Original name
An extensive immunohistochemical analysis of 290 ovarian adult granulosa cell tumors with 29 markers
Authors
NEMEJCOVA, Kristyna (203 Czech Republic), Adam SAFANDA (203 Czech Republic), Michaela KENDALL BARTU (203 Czech Republic), Romana MICHALKOVA (203 Czech Republic), Marian SVAJDLER (203 Czech Republic), Tetiana SHATOKHINA (804 Ukraine), Jan LACO (203 Czech Republic), Radoslav MATEJ (203 Czech Republic), Gabor MEHES (348 Hungary), Jana DROZENOVA (203 Czech Republic), Jitka HAUSNEROVÁ (203 Czech Republic, belonging to the institution), Zuzana SPURKOVA (203 Czech Republic), Monika NÁLEŽINSKÁ (203 Czech Republic, belonging to the institution) and Pavel DUNDR (203 Czech Republic)
Edition
Virchows Archiv, New York, Springer, 2024, 0945-6317
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30109 Pathology
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 3.500 in 2022
Organization unit
Faculty of Medicine
UT WoS
001251527400001
Keywords in English
Ovarian tumors; Sex cord-stromal tumors; Granulosa cell tumors; Immunohistochemistry
Tags
International impact, Reviewed
Změněno: 31/10/2024 15:02, Mgr. Tereza Miškechová
Abstract
V originále
The current knowledge about the immunohistochemical features of adult granulosa cell tumor (AGCT) is mostly limited to the "traditional" immunohistochemical markers of sex cord differentiation, such as inhibin, calretinin, FOXL2, SF1, and CD99. Knowledge about the immunohistochemical markers possibly used for predictive purpose is limited. In our study, we focused on the immunohistochemical examination of 290 cases of AGCT classified based on strict diagnostic criteria, including molecular testing. The antibodies used included 12 of the "diagnostic" antibodies already examined in previous studies, 10 antibodies whose expression has not yet been examined in AGCT, and 7 antibodies with possible predictive significance, including the expression of HER2, PD-L1, CTLA4, and 4 mismatch repair (MMR) proteins. The results of our study showed expression of FOXL2, SF1, CD99, inhibin A, calretinin, ER, PR, AR, CKAE1/3, and CAIX in 98%, 100%, 90%, 78%, 45%, 41%, 94%, 82%, 26%, and 9% of AGCT, respectively. GATA3, SATB2, napsin A, MUC4, TTF1, and CD44 were all negative. PTEN showed a loss of expression in 71% of cases and DPC4 in 4% of cases. The aberrant staining pattern (overexpression) of p53 was found in 1% (3/268) of cases, 2 primary tumors, and 1 recurrent case. Concerning the predictive markers, the results of our study showed that AGCT is microsatellite stable, do not express PD-L1, and are HER2 negative. The CTLA4 expression was found in almost 70% of AGCT tumor cells.
Links
LM2023033, research and development project |
|